Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

por Zobel, Emilie H., Ripa, Rasmus S., von Scholten, Bernt J., Rotbain Curovic, Viktor, Kjaer, Andreas, Hansen, Tine W., Rossing, Peter, Størling, Joachim
Publicado 2021

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

por Jensen, Jacob K., Zobel, Emilie H., von Scholten, Bernt J., Rotbain Curovic, Viktor, Hansen, Tine W., Rossing, Peter, Kjaer, Andreas, Ripa, Rasmus S.
Publicado 2021

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

por Rotbain Curovic, Viktor, Houlind, Morten B., Hansen, Tine W., Eugen-Olsen, Jesper, Laursen, Jens Christian, Eickhoff, Mie K., Persson, Frederik, Rossing, Peter
Publicado 2022

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

por Zobel, Emilie H, Wretlind, Asger, Ripa, Rasmus S, Rotbain Curovic, Viktor, von Scholten, Bernt J, Suvitaival, Tommi, Hansen, Tine W, Kjær, Andreas, Legido-Quigley, Cristina, Rossing, Peter
Publicado 2021

Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes

por Ferreira-Divino, Luis F., Suvitaival, Tommi, Rotbain Curovic, Viktor, Tofte, Nete, Trošt, Kajetan, Mattila, Ismo M., Theilade, Simone, Winther, Signe A., Hansen, Tine W., Frimodt-Møller, Marie, Legido-Quigley, Cristina, Rossing, Peter
Publicado 2022